Vertex Pharmaceuticals Hits Day Low of $457.36 Amid Price Pressure

Vertex Pharmaceuticals, Inc. has experienced a notable decline today, with the stock dropping by 3.57% as of March 5, 2026. The stock reached an intraday low of USD 457.36, reflecting a challenging trading session. Over the past week, Vertex has seen a decrease of 4.02%, while its performance over the last month shows a modest gain of 0.44%. However, the stock's year-to-date performance stands at 1.65%, indicating some resilience compared to the broader market. In terms of financial metrics, Vertex boasts a strong operating cash flow of USD 3,631.4 million, alongside a high interest coverage ratio of 41,015.15. The company has a return on equity of 23.70%, suggesting an attractive valuation with a price-to-book ratio of 6.26. Despite the recent downturn, institutional holdings remain robust at 97.13%, reflecting confidence from larger investors. Vertex's performance over the past three years shows a gain of 58.62%, although it has underperformed the S&P 500 over the last year, which has seen an 18.89% increase.